BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7(28): 2811-2818 [PMID: 26668692 DOI: 10.4254/wjh.v7.i28.2811] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Akhmedov VA, Gaus OV. Involvement of the hepatobiliary system and pancreas in obesity. Terapevticheskii arkhiv 2017;89:128-33. [DOI: 10.17116/terarkh2017891128-133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, Sim D, Jarr K, Spear ET, Singh G, Namkoong H, Bittinger K, Fischbach MA, Sonnenburg JL, Habtezion A. Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. Cell Host Microbe 2020;27:659-670.e5. [PMID: 32101703 DOI: 10.1016/j.chom.2020.01.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 31.0] [Reference Citation Analysis]
3 Zhang H, Dong M, Liu X. Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. Exp Ther Med 2021;22:991. [PMID: 34345273 DOI: 10.3892/etm.2021.10423] [Reference Citation Analysis]
4 Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
5 Chen T, Reich NW, Bell N, Finn PD, Rodriguez D, Kohler J, Kozuka K, He L, Spencer AG, Charmot D, Navre M, Carreras CW, Koo-mccoy S, Tabora J, Caldwell JS, Jacobs JW, Lewis JG. Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5). J Med Chem 2018;61:7589-613. [DOI: 10.1021/acs.jmedchem.8b00308] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
6 Kuna L, Bozic I, Kizivat T, Bojanic K, Mrso M, Kralj E, Smolic R, Wu GY, Smolic M. Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives. Curr Drug Metab 2018;19:830-8. [PMID: 29788883 DOI: 10.2174/1389200219666180523095355] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
7 Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019;5:1-10. [PMID: 30915401 DOI: 10.5114/ceh.2019.83151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
8 Talavera-Urquijo E, Beisani M, Balibrea JM, Alverdy JC. Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review. Surg Obes Relat Dis 2020;16:1361-9. [PMID: 32336663 DOI: 10.1016/j.soard.2020.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Takada S, Matsubara T, Fujii H, Sato-Matsubara M, Daikoku A, Odagiri N, Amano-Teranishi Y, Kawada N, Ikeda K. Stress can attenuate hepatic lipid accumulation via elevation of hepatic β-muricholic acid levels in mice with nonalcoholic steatohepatitis. Lab Invest 2021;101:193-203. [PMID: 33303970 DOI: 10.1038/s41374-020-00509-x] [Reference Citation Analysis]
10 Chevre R, Trigueros-Motos L, Castaño D, Chua T, Corlianò M, Patankar JV, Sng L, Sim L, Juin TL, Carissimo G, Ng LFP, Yi CNJ, Eliathamby CC, Groen AK, Hayden MR, Singaraja RR. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. FASEB J 2018;32:3792-802. [PMID: 29481310 DOI: 10.1096/fj.201701084RR] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
11 Hu YB, Liu XY, Zhan W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Des Devel Ther 2018;12:2213-21. [PMID: 30038487 DOI: 10.2147/DDDT.S170518] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
12 Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-021-00566-7] [Reference Citation Analysis]
13 Finn PD, Rodriguez D, Kohler J, Jiang Z, Wan S, Blanco E, King AJ, Chen T, Bell N, Dragoli D, Jacobs JW, Jain R, Leadbetter M, Siegel M, Carreras CW, Koo-McCoy S, Shaw K, Le C, Vanegas S, Hsu IH, Kozuka K, Okamoto K, Caldwell JS, Lewis JG. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. Am J Physiol Gastrointest Liver Physiol 2019;316:G412-24. [PMID: 30605011 DOI: 10.1152/ajpgi.00300.2018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
14 Akhmedov VA, Gaus OV. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. Terapevticheskii arkhiv 2019;91:143-8. [DOI: 10.26442/00403660.2019.02.000051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Dong R, Yang X, Wang C, Liu K, Liu Z, Ma X, Sun H, Huo X, Fu T, Meng Q. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor. Phytomedicine 2019;53:134-42. [PMID: 30668392 DOI: 10.1016/j.phymed.2018.09.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
16 Zheng J, Ye C, Hu B, Yang H, Yao Q, Ma J, Liu Y, Liu H. Bile acid profiles in bile and feces of obese mice by a high-performance liquid chromatography-tandem mass spectrometry. Biotechnol Appl Biochem 2020. [PMID: 33140486 DOI: 10.1002/bab.2055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Liu N, Mu H, Zheng JM, Liang CD. Expression of α-adrenergic receptor (AR), β1-AR and β2-AR in liver tissue of nonalcoholic fatty liver disease rats. Shijie Huaren Xiaohua Zazhi 2016; 24(6): 909-914 [DOI: 10.11569/wcjd.v24.i6.909] [Reference Citation Analysis]
18 Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280-295. [PMID: 29154964 DOI: 10.1016/j.jhep.2017.11.014] [Cited by in Crossref: 257] [Cited by in F6Publishing: 247] [Article Influence: 51.4] [Reference Citation Analysis]
19 Yu Q, Jiang Z, Zhang L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther 2018;190:81-90. [PMID: 29684468 DOI: 10.1016/j.pharmthera.2018.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
20 Na J, Choi SA, Khan A, Huh JY, Piao L, Hwang I, Ha H, Park YH. Integrative Omics Reveals Metabolic and Transcriptomic Alteration of Nonalcoholic Fatty Liver Disease in Catalase Knockout Mice. Biomol Ther (Seoul) 2019;27:134-44. [PMID: 30630288 DOI: 10.4062/biomolther.2018.175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
23 Bozic M, Guzmán C, Benet M, Sánchez-Campos S, García-Monzón C, Gari E, Gatius S, Valdivielso JM, Jover R. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. J Hepatol 2016;65:748-57. [PMID: 27245430 DOI: 10.1016/j.jhep.2016.05.031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
24 Li X, Zheng S, Ma X, Cheng K, Wu G. Effects of dietary protein and lipid levels on the growth performance, feed utilization, and liver histology of largemouth bass (Micropterus salmoides). Amino Acids 2020;52:1043-61. [PMID: 32683495 DOI: 10.1007/s00726-020-02874-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
25 Bensalem A, Murtaza B, Hichami A, Khan AS, Oulamara H, Merlen G, Berrichi M, Agli AN, Tordjmann T, Khan NA. Bile acid receptor TGR5 is critically involved in preference for dietary lipids and obesity. J Nutr Biochem 2020;76:108298. [PMID: 31812910 DOI: 10.1016/j.jnutbio.2019.108298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
26 Duan XP, Meng Q, Liu KX. Nuclear receptor FXR: A potential therapeutic target for non-alcoholic steatohepatitis. Shijie Huaren Xiaohua Zazhi 2016; 24(15): 2289-2297 [DOI: 10.11569/wcjd.v24.i15.2289] [Reference Citation Analysis]
27 Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017;65:350-362. [PMID: 27358174 DOI: 10.1002/hep.28709] [Cited by in Crossref: 240] [Cited by in F6Publishing: 228] [Article Influence: 40.0] [Reference Citation Analysis]
28 Li H, Xi Y, Xin X, Tian H, Hu Y. Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis. Nutr Metab (Lond) 2020;17:34. [PMID: 32377219 DOI: 10.1186/s12986-020-00454-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Mansini AP, Peixoto E, Thelen KM, Gaspari C, Jin S, Gradilone SA. The cholangiocyte primary cilium in health and disease. Biochim Biophys Acta Mol Basis Dis 2018;1864:1245-53. [PMID: 28625917 DOI: 10.1016/j.bbadis.2017.06.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
30 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
31 Kusu H, Yoshida H, Kudo M, Okuyama M, Harada N, Tsuji‐naito K, Akagawa M. Tomatidine Reduces Palmitate‐Induced Lipid Accumulation by Activating AMPK via Vitamin D Receptor‐Mediated Signaling in Human HepG2 Hepatocytes. Mol Nutr Food Res 2019;63:1801377. [DOI: 10.1002/mnfr.201801377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
32 Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Reference Citation Analysis]
33 Sun J, Zhang J, Wang X, Ji F, Ronco C, Tian J, Yin Y. Gut-liver crosstalk in sepsis-induced liver injury. Crit Care 2020;24:614. [PMID: 33076940 DOI: 10.1186/s13054-020-03327-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Dong R, Wang J, Gao X, Wang C, Liu K, Wu J, Liu Z, Sun H, Ma X, Meng Q. Yangonin protects against estrogen–induced cholestasis in a farnesoid X receptor-dependent manner. European Journal of Pharmacology 2019;857:172461. [DOI: 10.1016/j.ejphar.2019.172461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018;4:55-71. [PMID: 29904722 DOI: 10.5114/ceh.2018.75955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kobayashi Y, Hara N, Sugimoto R, Mifuji-Moroka R, Tanaka H, Eguchi A, Iwasa M, Hasegawa H, Iwata K, Takei Y, Taguchi O. The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD). Intern Med. 2017;56:755-762. [PMID: 28381740 DOI: 10.2169/internalmedicine.56.7796] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
37 Lin Z, Ye W, Zu X, Xie H, Li H, Li Y, Zhang W. Integrative metabolic and microbial profiling on patients with Spleen-yang-deficiency syndrome. Sci Rep 2018;8:6619. [PMID: 29700349 DOI: 10.1038/s41598-018-24130-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
38 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
39 Hu J, Hong W, Yao KN, Zhu XH, Chen ZY, Ye L. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway. World J Gastroenterol 2019; 25(12): 1492-1501 [PMID: 30948912 DOI: 10.3748/wjg.v25.i12.1492] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
40 Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 2016;1:56-67. [PMID: 28404113 DOI: 10.1016/S2468-1253(16)30011-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 31] [Article Influence: 15.2] [Reference Citation Analysis]
41 Kaska L, Sledzinski T, Chomiczewska A, Dettlaff-Pokora A, Swierczynski J. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World J Gastroenterol 2016; 22(39): 8698-8719 [PMID: 27818587 DOI: 10.3748/wjg.v22.i39.8698] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
42 Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707-1718. [PMID: 28687459 DOI: 10.1016/j.drudis.2017.06.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 18.4] [Reference Citation Analysis]
43 Schonewille M, de Boer JF, Groen AK. Bile salts in control of lipid metabolism: . Current Opinion in Lipidology 2016;27:295-301. [DOI: 10.1097/mol.0000000000000303] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
44 Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol 2019;8:247-67. [PMID: 31004828 DOI: 10.1016/j.jcmgh.2019.04.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
45 Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 20.2] [Reference Citation Analysis]
46 Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, Qi Y, Peng JY. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(30): 6890-6905 [PMID: 27570425 DOI: 10.3748/wjg.v22.i30.6890] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
47 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]